Respiratory Medicine - British Columbia Medical Association

3. Number of PH clinic in 200915Swiston76 clinicsLevy16 clinicsOstrow17 clinicsRespiratory Ambulatory Clinics3 clinicsScleroderma Clinics6 clinicsPACH Clinics (congenital heart disease)6 clinicsTotal 124Note: the number of clinics needed to cope with the increase in referrals and follow-ups isestimated to rise by approximately 10% per year. Thus in 2011 the expected number of clinicswould be 1504.Number of new patient consultations and follow up appointments seen in the VGH PHclinic in 2009New patient consultations 125Follow up appointments 459Total 584Note: these numbers do not include those seen in the Scleroderma clinic or the PACH clinic.References1. Simonneau, G., et al., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2009.54(1 Suppl): p. S43-54.2. Tuder, R.M., et al., Development and pathology of pulmonary hypertension. J Am Coll Cardiol, 2009. 54(1Suppl): p. S3-9.3. Gaine, S.P. and L.J. Rubin, Primary pulmonary hypertension. Lancet, 1998. 352(9129): p. 719-25.4. Humbert, M., O. Sitbon, and G. Simonneau, Treatment of pulmonary arterial hypertension. N Engl J Med,2004. 351(14): p. 1425-36.5. D'Alonzo, G.E., et al., Survival in patients with primary pulmonary hypertension. Results from a nationalprospective registry. Ann Intern Med, 1991. 115(5): p. 343-9.6. Barst, R.J., et al., Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J AmColl Cardiol, 2009. 54(1 Suppl): p. S78-84.7. Gomberg-Maitland, M. and H. Olschewski, Prostacyclin therapies for the treatment of pulmonary arterialhypertension. Eur Respir J, 2008. 31(4): p. 891-901.8. Keogh, A.M., et al., Interventional and surgical modalities of treatment in pulmonary hypertension. J AmColl Cardiol, 2009. 54(1 Suppl): p. S67-77.9. McLaughlin, V.V., A. Shillington, and S. Rich, Survival in Primary Pulmonary Hypertension: The Impactof Epoprostenol Therapy. Circulation, 2002. 106(12): p. 1477-1482.